Technology Appraisal Guidance No. 282
Source: National Institute for Health and Care Excellence
1.1 Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if:
- the person has a forced vital capacity (FVC) between 50% and 80% predicted and
- the manufacturer provides pirfenidone with the discount agreed in the patient access scheme.
1.2 Treatment with pirfenidone that is recommended according to 1.1 should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period).
1.3 People currently receiving pirfenidone that is not recommended according to 1.1 should have the option to continue treatment until they and their clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA282
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: email@example.com
Pirfenidone for treating idiopathic pulmonary fibrosis.
Issue Date: April 2013